Amylyx Pharmaceuticals (NASDAQ:AMLX) Issues Earnings Results, Misses Estimates By $0.03 EPS

Amylyx Pharmaceuticals (NASDAQ:AMLX) released its quarterly earnings results on Thursday. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03), FiscalAI reports.

Here are the key takeaways from Amylyx Pharmaceuticals’ conference call:

• LUCIDITY top-line data is expected in late August or early September 2026 after the final participant completed the 16-week study period; database cleaning and locking are still underway, and management remains blinded to the results.
• Amylyx reported $250.8 million in cash and marketable securities at quarter-end and expects its cash runway to extend into 2028, covering anticipated avexitide milestones, including a potential 2027 launch.
• Commercial preparations are advancing ahead of a potential avexitide approval, including field medical deployment, key commercial hires, an HCP and patient education campaign, and plans to target treatment centers with concentrated PBH populations.
• Management estimates approximately 160,000 U.S. patients have post-bariatric hypoglycemia and cites high endocrinologist intent to treat with an approved therapy; a dedicated ICD-10 code becomes effective October 1, 2026, potentially improving recognition and tracking of the condition.
• Q2 operating expenses rose 7% year over year to $45.7 million, driven partly by higher legal costs, including a one-time charge, and increased commercial investment; avexitide’s approval, label breadth, and launch timing remain dependent on the pending phase III data and FDA review.

Amylyx Pharmaceuticals Trading Up 10.7%

AMLX stock traded up $2.34 during midday trading on Thursday, hitting $24.19. The company had a trading volume of 3,537,737 shares, compared to its average volume of 1,860,869. The stock has a market cap of $2.69 billion, a price-to-earnings ratio of -16.13 and a beta of -0.21. Amylyx Pharmaceuticals has a 52 week low of $7.48 and a 52 week high of $24.36. The stock’s 50 day moving average price is $17.19 and its 200 day moving average price is $15.71.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on AMLX shares. HC Wainwright restated a “buy” rating and issued a $34.00 target price on shares of Amylyx Pharmaceuticals in a research report on Monday, June 8th. Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Guggenheim upped their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. Citigroup increased their target price on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a report on Monday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $25.38.

Insider Activity

In related news, insider Gina Mazzariello sold 15,000 shares of Amylyx Pharmaceuticals stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $18.32, for a total value of $274,800.00. Following the transaction, the insider directly owned 194,090 shares of the company’s stock, valued at $3,555,728.80. The trade was a 7.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 10.90% of the company’s stock.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Meeder Asset Management Inc. purchased a new stake in shares of Amylyx Pharmaceuticals during the fourth quarter worth about $25,000. California State Teachers Retirement System purchased a new position in Amylyx Pharmaceuticals during the 2nd quarter valued at about $28,000. Caitong International Asset Management Co. Ltd increased its holdings in Amylyx Pharmaceuticals by 1,116.9% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,454 shares of the company’s stock valued at $54,000 after purchasing an additional 4,088 shares during the period. BNP Paribas Financial Markets raised its position in Amylyx Pharmaceuticals by 433.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock valued at $47,000 after purchasing an additional 5,904 shares during the last quarter. Finally, Legal & General Group Plc purchased a new stake in Amylyx Pharmaceuticals in the 2nd quarter worth approximately $47,000. Hedge funds and other institutional investors own 95.84% of the company’s stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.